Treatment Patterns in Patients With Eosinophilic Oesophagitis Referred for Expert Consultation
BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) patients deemed treatment-refractory are frequently referred to tertiary centres. We aimed to characterize expert perspectives on patients referred for refractory EoE, including its causes, prevalence, and evaluation. METHODS: We conducted an anonymous and blinded cross-sectional survey of international EoE experts (n = 52) assessing provider characteristics, referral patterns, perceived causes of treatment failure, diagnostic approaches, and prior therapies. Descriptive statistics and subgroup analyses were performed. RESULTS: Respondents were predominantly gastroenterologists (77%) and practiced in academic settings (87%) with high EoE volume. Experts estimated that true refractoriness to medical and diet therapy was 15% [IQR 10-25], median 31% [20-50], respectively. Patients referred for perceived refractory EoE had been treated with PPIs (80%), topical steroids (55%), and elimination diets (45%); dupilumab (10%) was infrequently trialled. Half of the patients referred had been on combination therapy. After referral, experts focused on assessing medication adherence (98%), dosing (92%), and administration technique (90%), with most repeating endoscopy (85%) and performing oesophageal dilation (42%). The causes of perceived refractory disease were subtherapeutic dosing (34%), incorrect medication administration (30.5%), inappropriate medication choice (26.5%), and dietary non-adherence (26%). Functional and behavioural contributors including co-existing oesophageal hypersensitivity (20%), ARFID (9%), and rumination syndrome (5%) were also reported. Experience in treating EoE patients assessed by less than or greater than 10 years did not affect most results. CONCLUSIONS: Among international experts, most referred EoE patients labelled as refractory had received suboptimal medical and dilation therapy. This highlights opportunities to optimize care along guideline recommendations prior to referral.
Authors
- Sydney Pomenti (ORCID: https://orcid.org/0000-0001-6728-8000)
- Alexa Choy (ORCID: https://orcid.org/0000-0003-2421-6327)
- David A. Katzka (ORCID: https://orcid.org/0000-0003-2307-2317)
- Nirmala Prabu Gonsalves (ORCID: https://orcid.org/0000-0003-0722-6099)
- Emma Fanuele
- Elina Stoffel
- Evan S. Dellon
Institutions
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- Medical University of South Carolina (US)
- Columbia University (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2026-08-27
- DOI
- https://doi.org/10.1111/apt.70951
- Primary Topic
- Eosinophilic Esophagitis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Celgene
- Regeneron Pharmaceuticals
- Celldex Therapeutics
- BioCryst
- Dr. Falk Pharma